Video
Dr. Christian Gisselbrecht on Defining Refractory Disease in DLBCL
Author(s):
Christian Gisselbrecht, MD, a Professor of Haematology in the Haemato-Oncology Department of Hôpital Saint-Louis, at Diderot University, Paris, discusses stratifying refractory disease in aggressive diffuse large b-cell lymphoma (DLBCL).
Christian Gisselbrecht, MD, a Professor of Haematology in the Haemato-Oncology Department of Hôpital Saint-Louis, at Diderot University, Paris, discusses stratifying refractory disease in aggressive diffuse large b-cell lymphoma (DLBCL).
Instead of just assuming a patient is refractory because they’ve relapsed, Gisselbrecht’s team wanted a more precise definition.
In collaboration with several companies and cancer centers, Gisselbrecht’s team determined several types of refractory patients.
By defining different groups of relapsed patients, prognostic factors can be determined for specific populations, says Gisselbrecht.
<<<
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
